Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide on Gastric Emptying in Type 1 Diabetes and Overweight/Obesity
NCT07803744Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) and obesity comparing Tirzepatide + Acetaminophen with Placebo + Acetaminophen (2 arms). Primary endpoints: Time of Maximum Observed Drug Concentration of Acetaminophen at 36 hours, Area Under the Concentration Versus Time Curve from Time Zero to Time t of Acetaminophen at 36 hours and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)obesity
Beyond the preview
Go deeper on NCT07803744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803744.